Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.
- Are Biopharma Companies Outsourcing Their Ability To Think?
- June 2026 — CDMO Opportunities And Threats Report
- The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable
- Defining Quality In A Sponsor-Owned QTPP Before The CDMO Even Starts
- ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies
- Reshoring Pressure Meets Manufacturing Reality
- CDMO Live Europe 2026: Partnerships For An Uncertain World
- Resilience, Risk, And Relationships: CDMO Live Europe 2026 Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Cell Collection Basics For The Transplant And CGT Industries
Breakthroughs in CAR T-cell and stem cell therapies depend on mastering cellular collection. Understanding these fundamentals is vital for advancing treatment efficacy and patient outcomes.
-
Microbial Recovery And Flow Performance With Membranes
Compare membrane materials and pore sizes to assess their impact on flow rate and microbial recovery. See how fast filtration and ≥90% organism recovery offer guidance for selecting reliable membranes.
-
Advanced Aseptic Filling Assembly Helium Integrity Testing
Helium leak testing offers unmatched sensitivity for detecting micro-leaks in single-use fill-finish systems. Learn how tighter leak thresholds can strengthen aseptic processing and regulatory confidence.
-
Oligonucleotide Purification And Synthesis
Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.
-
A Faster Path To Genomic Medicine Feasibility
Life Edit accelerates genomic medicine by comparing five editing modalities, engineering new enzymes, and rapidly pinpointing optimal strategies that boost feasibility, cut risk, and speed clinical progress.
-
Automated Enrichment Of Human CD34+ Cells
Discover an automated strategy for enriching CD34+ cells, combining streamlined processing, strong purity and viability metrics, and reduced hands-on effort to support stem cell engineering.
-
Long-Term Container Closure Integrity Testing Of Vial-Stopper-Seal Combinations
The study was designed to investigate CCI over a period of 24 months at ambient, ultra-low and cryogenic temperatures for serum-stopper samples and at ambient temperature for lyo-stopper samples.
-
Mold In Cleanrooms: A Persistent Threat And The Case For Proactive Bio-Decontamination
Learn how a comprehensive investigation and systems-level bio-decontamination strategy successfully eliminated persistent mold contamination in a vaccine manufacturing facility's high-risk area.
-
Optimize Your Approach To mAb Development
To meet the growing demand for mAbs and their variants, it is important to leverage opportunities for optimization as well as work with suppliers that have the resources to help your workflow thrive.
-
Evaluating Clone Performance And Cell-Specific Productivity
See how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.
NEWSLETTER ARCHIVE
- 08.14.26 -- The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue
- 08.13.26 -- New Resources: MSC Manufacturing, Expansion, and Scale-Up Technologies
- 08.13.26 -- Building A Self-Driving Lab For LNP Development
- 08.12.26 -- Better Data For Cell & Gene Therapy Development
- 08.12.26 -- Tariffs, FDA Chaos, And BioSecure: How CDMOs Should Operate
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
- Solving Vector Yield Challenges Starts Long Before Manufacturing
- Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors
- FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections